Equillium, Inc. has secured $50 million in financing, with an initial tranche of $30 million, to advance EQ504 for ulcerative colitis, led by healthcare investors.
Amount Raised
$50 Million
Round Type
Funding Round
San DiegoBiotechnologyHealth CareScience And EngineeringInvestors
Description
Equillium, Inc announced a financing of up to $50 million to support the development of its novel drug, EQ504, targeting ulcerative colitis. The funding includes an initial $30 million to provide operational runway through 2027. Their Phase 1 clinical study for EQ504 is set to start in mid-2026. CEO Bruce Steel highlighted the potential for EQ504 to be a first-in-class therapeutic for this condition.
Quick answer
Equillium raised $50 Million in a Funding Round round, dated November 13, 2025. Investors: Woodline Partners LP, Coastlands Capital, Adage Capital Partners, Janus Henderson and Adar1 Capital Management. Equillium is based in San Diego, California, United States.
- How much did Equillium raise?
- Equillium raised $50 Million in a Funding Round round on November 13, 2025.
- Who invested in Equillium?
- Woodline Partners LP, Coastlands Capital, Adage Capital Partners, Janus Henderson and Adar1 Capital Management are named as investors in this round.
- What does Equillium do?
- Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need.
- Where is Equillium based and how big is it?
- Equillium is based in San Diego, California, United States.
- Who are the decision-makers at Equillium?
- Fundz holds 2 contacts at Equillium, including the Co-founder & Chief Scientific Officer at Equillium, Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Equillium that raised within 45 days of this round, from Fundz verified event records.
- Vyriad raised $25M (Series B) on December 23, 2025.
- MAIA Biotechnology raised $1.5M on December 22, 2025.
- Atavistik Bio raised $120M (Series B) on December 21, 2025.
- Enveric Biosciences raised $107K on December 12, 2025.
- Aprea Therapeutics raised $3.1M on December 10, 2025.
- TandemAI raised $22M (Series A) on November 14, 2025.
Who to call at Equillium, and when
A new round usually means Equillium is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Equillium raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Equillium, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Equillium. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Equillium raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Equillium raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.